Sing2016 M2SR H3N2 / FluGen - LARVOL DELTA

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine (clinicaltrials.gov) - P1 | N=140 | Terminated | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Terminated; Lack of product and funding.

Trial termination • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine (clinicaltrials.gov) - P1 | N=140 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting | N=200 ➔ 140 | Trial completion date: Nov 2023 ➔ Apr 2024 | Trial primary completion date: Nov 2023 ➔ Apr 2024

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Phase classification: P1b ➔ P1

Phase classification • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old (clinicaltrials.gov) - P1b | N=122 | Completed | Sponsor: FluGen Inc | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years (PRNewswire) - "FluGen...today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company's investigational supra-seasonal intranasal influenza (flu) vaccine, in volunteers ages 6 months to 17 years old. This study is the first of its kind to evaluate M2SR in children under 9 years old...The randomized, double-blind, dose-escalating, age de-escalating, placebo-controlled, Phase 1b study, (clinicaltrials.gov NCT04960397) is designed to evaluate a monovalent Singapore 2016 H3N2 M2SR influenza A vaccine in children. The primary endpoint is to measure the safety and tolerability of M2SR."

Enrollment closed • Infectious Disease • Influenza

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old (clinicaltrials.gov) - P1b | N=122 | Active, not recruiting | Sponsor: FluGen Inc | Trial completion date: Sep 2022 ➔ Dec 2022

Trial completion date • Infectious Disease • Respiratory Diseases